Clearside Biomedical, Inc.

NasdaqGM:CLSD Voorraadrapport

Marktkapitalisatie: US$75.5m

Clearside Biomedical Beheer

Beheer criteriumcontroles 2/4

Clearside Biomedical's CEO is George Lasezkay, appointed in Apr 2019, has a tenure of 5.58 years. total yearly compensation is $1.54M, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $386.59K. The average tenure of the management team and the board of directors is 2.3 years and 5.4 years respectively.

Belangrijke informatie

George Lasezkay

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris35.6%
Dienstverband CEO5.6yrs
Eigendom CEO0.5%
Management gemiddelde ambtstermijn2.3yrs
Gemiddelde ambtstermijn bestuur5.4yrs

Recente managementupdates

Recent updates

Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 06
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Jun 24
We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate

Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Nov 12
Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation

Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Aug 11
Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)

Clearside Biomedical Q2 2022 Earnings Preview

Aug 08

Clearside Biomedical: A Pivotal 2022 Ahead

Apr 13

Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play

Dec 22

Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Sep 30
Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business

Clearside's Value Proposition Is Far From Clear

Aug 07

We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Jun 17
We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth

Clearside Biomedical climbs after positive results from early-stage wet AMD trial

Jun 15

Clearside Biomedical resubmits eye treatment XIPERE NDA

May 03

If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Feb 16
If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns

Analyse CEO-vergoeding

Hoe is George Lasezkay's beloning veranderd ten opzichte van Clearside Biomedical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$33m

Mar 31 2024n/an/a

-US$35m

Dec 31 2023US$2mUS$547k

-US$32m

Sep 30 2023n/an/a

-US$37m

Jun 30 2023n/an/a

-US$36m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$532k

-US$33m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$2m

Mar 31 2022n/an/a

US$83k

Dec 31 2021US$2mUS$516k

US$376k

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$23m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$1mUS$503k

-US$18m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$1mUS$385k

-US$31m

Sep 30 2019n/an/a

-US$49m

Jun 30 2019n/an/a

-US$67m

Mar 31 2019n/an/a

-US$82m

Dec 31 2018US$150kn/a

-US$83m

Sep 30 2018n/an/a

-US$78m

Jun 30 2018n/an/a

-US$72m

Mar 31 2018n/an/a

-US$65m

Dec 31 2017US$167kn/a

-US$59m

Compensatie versus markt: George's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: George's compensation has increased whilst the company is unprofitable.

CEO

George Lasezkay (72 yo)

5.6yrs

Tenure

US$1,538,627

Compensatie

Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
George Lasezkay
President5.6yrsUS$1.54m0.51%
$ 386.6k
Charles Deignan
Chief Financial Officer12.8yrsUS$854.41k0.45%
$ 340.8k
Jenny Kobin
Head of Investor Relationsno datageen gegevensgeen gegevens
Rick McElheny
Senior Vice President of Corporate Development & Alliance Management2.2yrsgeen gegevensgeen gegevens
Rafael Andino
Senior Vice President of Engineering & Manufacturing1.8yrsgeen gegevensgeen gegevens
Susan Coultas
Chief Clinical Officer2.4yrsgeen gegevensgeen gegevens
Ngai Hang Chong
Chief Medical Officerless than a yeargeen gegevens0.085%
$ 64.1k
Leslie Zacks
Secretaryno datageen gegevensgeen gegevens

2.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: CLSD's management team is considered experienced (2.3 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
George Lasezkay
President7.3yrsUS$1.54m0.51%
$ 386.6k
Christy Shaffer
Independent Director12.8yrsUS$86.08k0.0059%
$ 4.4k
Benjamin Yerxa
Independent Director2.7yrsUS$88.58k0.024%
$ 18.1k
Jeffrey Edwards
Independent Director6.2yrsUS$88.58k0%
$ 0
Clay Thorp
Independent Chair of the Board12.8yrsUS$96.08k0.054%
$ 40.9k
Carl Regillo
Member of Scientific Advisory Board4.6yrsgeen gegevensgeen gegevens
William Humphries
Independent Director12.8yrsUS$91.71k0.068%
$ 51.5k
David Boyer
Member of Scientific Advisory Board4.6yrsgeen gegevensgeen gegevens
Nancy Hutson
Independent Director4.6yrsUS$85.46k0.12%
$ 93.9k
Richard Croarkin
Independent Director8.8yrsUS$91.08k0%
$ 0
Arshad Khanani
Member of Scientific Advisory Board1.6yrsgeen gegevensgeen gegevens
Lejla Vajzovic
Member of Scientific Advisory Board1.6yrsgeen gegevensgeen gegevens

5.4yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: CLSD's board of directors are considered experienced (5.4 years average tenure).